The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Jul. 30, 2019
Filed:
Dec. 21, 2016
Applicants:
Ose Immunotherapeutics, Nantes, FR;
Institut National DE LA Sante ET DE LA Recherche Medicale (Inserm), Paris, FR;
Inventors:
Assignees:
Institut National de la Sante et de la Recherche Medicale, Paris, FR;
OSE Immunotherapeutics, Nantes, FR;
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C07K 16/28 (2006.01); A61K 39/395 (2006.01); C07K 19/00 (2006.01); A61K 47/60 (2017.01); A61K 39/00 (2006.01);
U.S. Cl.
CPC ...
C07K 16/2818 (2013.01); A61K 39/3955 (2013.01); A61K 47/60 (2017.08); C07K 16/2896 (2013.01); C07K 19/00 (2013.01); A61K 2039/505 (2013.01); C07K 2317/24 (2013.01); C07K 2317/524 (2013.01); C07K 2317/526 (2013.01); C07K 2317/53 (2013.01); C07K 2317/55 (2013.01); C07K 2317/56 (2013.01); C07K 2317/64 (2013.01); C07K 2317/76 (2013.01);
Abstract
The invention relates to humanized antibodies directed against the human lymphocyte receptor CD28. When used in a monovalent form these antibodies are antagonists, i.e. capable of blocking of the CD28/B7 interaction, without activating CD28. These antibodies can be used in particular as therapeutic agents for blocking T cell activation through the CD28 receptor.